Bimatoprost — Discount Pricing
Bimatoprost is not confirmed for no-additional-cost pricing. Discount pricing may be available; confirm the price with the dispensing pharmacy.
Bimatoprost Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Discount pricing may be available |
| Typical Retail | $202.00 |
Discount pricing may be available; confirm the price with the dispensing pharmacy.
About Bimatoprost
Bimatoprost is a prescription medication. Ask your doctor if Bimatoprost is right for you.
How to Check Bimatoprost Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
Bimatoprost at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Ophthalmology
About Bimatoprost
Bimatoprost is a versatile medication primarily used to manage glaucoma and enhance eyelash growth. Understanding how it works and its typical costs is crucial. At TheDrugClub, we're dedicated to helping you access your necessary prescriptions, like bimatoprost, at more affordable prices, ensuring your health doesn't break the bank.
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.
What Bimatoprost is approved for (FDA label)
Bimatoprost ophthalmic solution, 0.03% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. Bimatoprost ophthalmic solution, 0.03% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. ( 1 )
Source: Read the full FDA label on DailyMed. Label effective date: September 9, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Bimatoprost (FDA label)
Ophthalmic solution containing bimatoprost 0.3 mg/mL . Ophthalmic solution containing 0.3 mg/mL of bimatoprost. ( 3 )
Source: FDA prescribing information (DailyMed). Set ID: f5c1c8c6-2a7f-482b-6ecf-9cabd3a6a5c1. SPL document ID: f930f4d2-0919-6682-9632-34ddb70fa31a. Label effective date: September 9, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Bimatoprost (FDA label)
The following adverse reactions are described elsewhere in the labeling: Pigmentation [see Warnings and Precautions ( 5.1 )] Eyelash Changes [see Warnings and Precautions ( 5.2 )] Intraocular Inflammation [see Warnings and Precautions ( 5.3 )] Macular Edema [see Warnings and Precautions ( 5.4 )] Hypersensitivity [ see Contraindications ( 4 )] Most common adverse reaction (45%) is conjunctival hyperemia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Source: FDA prescribing information (DailyMed). Set ID: f5c1c8c6-2a7f-482b-6ecf-9cabd3a6a5c1. SPL document ID: f930f4d2-0919-6682-9632-34ddb70fa31a. Label effective date: September 9, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Bimatoprost (FDA label)
Bimatoprost ophthalmic solution, 0.03% is contraindicated in patients with hypersensitivity to bimatoprost or to any of the ingredients [see Adverse Reactions ( 6.2 )] . Hypersensitivity.
Source: FDA prescribing information (DailyMed). Set ID: f5c1c8c6-2a7f-482b-6ecf-9cabd3a6a5c1. SPL document ID: f930f4d2-0919-6682-9632-34ddb70fa31a. Label effective date: September 9, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Bimatoprost (FDA label)
Pigmentation: Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur. Iris pigmentation is likely to be permanent. ( 5.1 ) Eyelash Changes: Gradual change to eyelashes including increased length, thickness and number of lashes. Usually reversible. ( 5.2 ) 5.1 Pigmentation Bimatoprost ophthalmic solution has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid) and eyelashes. Pigmentation is expected to increase as long as bimatoprost is administered. The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of bimatoprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation.
Source: FDA prescribing information (DailyMed). Set ID: f5c1c8c6-2a7f-482b-6ecf-9cabd3a6a5c1. SPL document ID: f930f4d2-0919-6682-9632-34ddb70fa31a. Label effective date: September 9, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.